StockDocs
Main Newswire Learn
Project by Matthew Castle Please send feedback to matthewgcastle@gmail.com
PHGE

Tessera Defense and Homeland Security Inc.

PHGE NYSE Services-Prepackaged Software EDGAR ↗
$1.85
+1.32 +250.38%

Key statistics

from XBRL data in SEC filings
Market cap ⓘ
$49.4M
Revenue (TTM) ⓘ
—
Net income (TTM) ⓘ
-$45.5M
EPS (TTM) ⓘ
$20.01
P/E ratio ⓘ
0.1
Dividend yield ⓘ
—
Free cash flow ⓘ
-$26.4M
Cash ⓘ
$347K
Total assets ⓘ
$28.2M
Gross margin ⓘ
—
52-week range ⓘ
$0.44 – $2.16

AI briefing

from the latest 10-K, 10-Q and 8-K events

BiomX Inc. is now a defense, security and critical infrastructure technology holding company operating through three Israeli subsidiaries, following the December 2025 discontinuation of its legacy phage-therapy programs.

What they do

BiomX conducts operations through Dr. Frucht Systems Ltd. (DFSL), Zorro Net Ltd. and X Security & Defense Ltd. DFSL develops proprietary LADAR (laser radar) detection systems for counter-UAS, perimeter and ground-intruder detection, marketed with detection accuracy rates of up to approximately 99%. Zorro Net provides AI-powered detection and deterrence systems for critical infrastructure. The company acquired 60% of DFSL on April 13, 2026 and all of Zorro Net on April 10, 2026, and began consolidating both businesses in the quarter ended June 30, 2026.

Revenue drivers

  • DFSL LADAR detection systems — Perimeter security and counter-UAS detection hardware and systems sold to security, defense and critical infrastructure customers; DFSL is 60%-owned and was acquired April 13, 2026, so it contributed only part of the June 2026 quarter.
  • Zorro Net AI detection and deterrence — AI-powered detection and deterrence systems for critical infrastructure, wholly acquired April 10, 2026; the first revenue from this business appears in the June 30, 2026 quarter.
  • X Security & Defense — Wholly owned subsidiary described as focused on security, defense and first-response technologies, including aerial firefighting and autonomous emergency response capabilities; no separate revenue figures were disclosed in the excerpts.
  • Legacy phage-therapy programs — Former clinical-stage phage business; the legacy clinical programs were discontinued and the former Israeli operating subsidiary, BiomX Ltd., entered insolvency proceedings in December 2025, so it is no longer a revenue source.

Recent performance

Revenue for the quarter ended June 30, 2026 was $332,000, the first period in which DFSL and Zorro Net results are consolidated and the first period the company recognized revenue from defense and security operations. Total assets were $28.2 million, total liabilities $10.6 million and shareholder equity $10.9 million as of June 30, 2026. Cash and equivalents were only $347,000 at June 30, 2026, against long-term debt of $247,000. Full-year 2025 net loss was $36.2 million, versus $17.7 million in 2024, with operating cash outflow of $26.4 million in 2025 and $37.0 million in 2024. Annual net losses have ranged from $17.7 million to $36.2 million each year from 2021 through 2025.

Strategy

Following discontinuation of the legacy phage-therapy clinical programs and the December 2025 insolvency proceedings of BiomX Ltd., the company shifted its strategic focus to the defense, security and critical infrastructure technology markets. It has assembled the new platform through acquisitions: a 60% stake in DFSL closed April 13, 2026, and Zorro Net was acquired April 10, 2026, alongside wholly owned X Security & Defense Ltd. The 10-Q frames these businesses as addressing counter-UAS, AI-powered command-and-control and video analytics, perimeter security and border defense, and first-response technologies. A 1-for-19 reverse stock split took effect November 25, 2025.

Risks

  • Very low cash balance — Cash and equivalents of $347,000 at June 30, 2026 is minimal relative to a company that reported a $36.2 million net loss in 2025 and $26.4 million of operating cash outflow.
  • Unproven new business model — The defense and security operations produced only $332,000 of revenue in their first consolidated quarter, so the platform's commercial traction is still unestablished.
  • Partial ownership of DFSL — BiomX owns only 60% of Dr. Frucht Systems Ltd., the subsidiary whose LADAR product is central to the described technology portfolio, so a portion of its economics accrues to minority holders.
  • Execution risk on recent acquisitions — DFSL and Zorro Net were acquired only in April 2026, and integration, consolidation and any related financing announced through the July, August and September 2026 8-K filings carry implementation risk.

Outlook

The filings describe the defense, security and critical infrastructure markets as rapidly growing, citing counter-UAS, AI command-and-control and perimeter security demand, but provide no specific revenue or earnings guidance. The company notes only that the June 30, 2026 quarter is the first period reflecting DFSL and Zorro Net consolidation and the first revenue from defense and security operations. The 10-K/A states that, except as described, it has not updated its disclosures for events after the original filing date.

Recent SEC filings

40 most recent
Annual, quarterly & current reports